카이노스메드
1,087KRWMarket close of 10/27 (Tue)
No trade that dayMarket close of 10/27 (Tue)
Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)1,087KRWFlat 0.00%
Preliminary · replaced once official KRX data for the same date is published
- Volume
- 0×10K shares
- 0 KRW
Open, high and low are not shown — the source has no bar for the reference date
Market close of 10/27 (Tue)
Where it sits in the 1-year range
2%2% of the way up from the lowest close in 1 year (252 sessions) · -80.4% from the high
Free · no sign-inSource from 2021-05-17
Points to check
- Daily moveto checkNo trades this day (0 shares)
- Earningsto check-5.8B KRWOperating income over the last four quarters -5.8B KRW (loss)
- Trading valuenot verifiedNo trading that day, so not compared with usual trading value
The other 2
- Recent filingsnot verified
- Foreign & institutionalnot verified
See the full check report
Quarterly results · Q1 2026
- Revenue370.34 million KRW
- vs. year ago
- +0.4%
- vs. prior quarter
- +21.8%
- Operating income-1.0B KRW
- vs. year ago
- Still a loss
- vs. prior quarter
- Still a loss
- Operating margin-273.2%
- vs. year ago
- +184.9 pp
- vs. prior quarter
- +482.6 pp
Quarterly operating income trend
As of the latest official close · 2026-10-27Valuation filing date · 2026-05-15Same sector · 바이오 R&D
Down -0.67%· 26 of 64 stocks up, preferred shares excluded · trading value 190.2B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -12.6% | Flat 0.00% | 51.8B KRW |
| 올릭스 | Close over the last 20 sessions -11.8% | Down -5.72% | 24.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -8.3% | Up +0.37% | 14.0B KRW |
| 리가켐바이오 | Close over the last 20 sessions -20.9% | Down -1.54% | 12.1B KRW |
| 페니트리움바이오 | Close over the last 20 sessions -4.2% | Up +14.41% | 9.8B KRW |
Schedule
- Next data 10/29 (Thu) after 08:50
Related news
Tables, financials, investor flows and filing history are in the Detailed view.
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 82% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.